Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNRHR | P30968 | 19/20 | 0.59 |
| ▸ | PARP1 | P09874 | 1/20 | 0.48 |
| ▸ | DHODH | Q02127 | 1/20 | 0.48 |
| ▸ | TACR2 | P21452 | 1/20 | 0.45 |
| ▸ | HRH2 | P25021 | 1/20 | 0.45 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.45 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.45 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.45 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5512568 | 0.94 | GNRHR (0.63) | GNRHRPARP1DHODH | |
| SCHEMBL6000819 | 0.93 | GNRHR (0.55) | GNRHRPARP1DHODHTACR2HRH2 | |
| SCHEMBL5513447 | 0.93 | GNRHR (0.56) | GNRHRPARP1DHODHTACR2HRH2 | |
| SCHEMBL5508960 | 0.93 | GNRHR (0.60) | GNRHRTACR2HRH2OPRM1OPRD1 | |
| SCHEMBL6001463 | 0.92 | GNRHR (0.58) | GNRHRTACR2HRH2OPRM1OPRD1 | |
| SCHEMBL6001305 | 0.92 | GNRHR (0.60) | GNRHR | |
| SCHEMBL5509921 | 0.91 | GNRHR (0.61) | GNRHRPARP1DHODHTACR2HRH2 | |
| SCHEMBL5506661 | 0.91 | GNRHR (0.59) | GNRHRPARP1DHODH | |
| SCHEMBL5511248 | 0.91 | GNRHR (0.63) | GNRHRPARP1DHODH | |
| SCHEMBL5510258 | 0.90 | GNRHR (0.59) | GNRHRPARP1DHODH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060111355-A1 | Gonadotropin releasing hormone receptor antagonists | WYETH (US) | 2006-05-25 | — | — | US | claimed |
| EP-1814866-A2 | GONADOTROPIN RELEASING HORMONE RECEPTOR ANTAGONISTS | Wyeth a Corporation of the State of Delaware (US) | 2007-08-08 | — | — | EP | disclosed |
| WO-2006058012-A2 | GONADOTROPIN RELEASING HORMONE RECEPTOR ANTAGONISTS | WYETH (US) | 2006-06-01 | — | — | WO | disclosed |
| US-20060111355-A1 | Gonadotropin releasing hormone receptor antagonists | WYETH (US) | 2006-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060111355-A1 | Gonadotropin releasing hormone receptor antagonists | GNRHR, LHCGR, GHRHR | GNRHR 1/4885PARP1 3548/4885DHODH 2941/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.